CANF Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.100

Open

2.980

VWAP

3.05

Vol

45.86K

Mkt Cap

6.64M

Low

2.950

Amount

139.89K

EV/EBITDA(TTM)

--

Total Shares

2.14M

EV

588.04K

EV/OCF(TTM)

--

P/S(TTM)

2.74

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Show More

Events Timeline

(ET)

2026-03-30

07:40:00

Can-Fite Signs Licensing Agreement with Vetbiolix, Projected Revenue of $325M

2026-03-17 (ET)

2026-03-17

08:00:00

Can-Fite Secures Patent for Namodenoson-Based Weight Loss Drug

2026-03-04 (ET)

2026-03-04

07:10:00

Can-Fite BioPharma Announces Phase IIa Results for Namodenoson

2026-02-17 (ET)

2026-02-17

07:20:00

Can-Fite BioPharma Publishes Study on Namodenoson

2026-02-09 (ET)

2026-02-09

07:20:00

Can-Fite Receives Canadian Patent Approval for Weight Loss Therapy

2026-02-05 (ET)

2026-02-05

07:20:00

Can-Fite BioPharma Patient Successfully Undergoes Liver Transplant

2026-01-20 (ET)

2026-01-20

07:10:00

Can-Fite BioPharma Completes Patient Enrollment in Pancreatic Cancer Trial

2025-12-26 (ET)

2025-12-26

07:10:00

Can-Fite BioPharma Secures Patent in Brazil for Sexual Dysfunction Treatment

News

Newsfilter

03-30Newsfilter

PinnedCan-Fite Signs Up to $325M Deal with Vetbiolix

seekingalpha

03-26seekingalpha

Can-Fite Biopharma Reports FY 2025 Financial Results

Newsfilter

03-26Newsfilter

Can-Fite BioPharma Reports 2025 Financial Results and Clinical Advances

moomoo

CAN-FITE ANNOUNCES 2025 FINANCIAL RESULTS AND CLINICAL ADVANCEMENTS, SHOWCASING PROMISING PHASE 2A DATA FOR PANCREATIC CANCER AND NINE-YEAR CANCER-FREE SURVIVAL IN LIVER CANCER PATIENTS

NASDAQ.COM

03-04NASDAQ.COM

Can-Fite BioPharma's Drug Trial Achieves Success

Benzinga

Can-Fite BioPharma's Drug Trial Success Boosts Shares

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -0.83, compared to its 5-year average forward P/E of -0.60. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.60

Current PE

-0.83

Overvalued PE

4.46

Undervalued PE

-5.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.12

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.58

Undervalued EV/EBITDA

-0.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

23.80

Current PS

243.93

Overvalued PS

68.03

Undervalued PS

-20.43

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks have have hit pivot bottom

Intellectia · 247 candidates

Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000

Ticker

Name

Market Cap$

Lifecore Biomedical Inc

149.91M

NovaGold Resources Inc

3.54B

GoldMining Inc

243.68M

Clearpoint Neuro Inc

282.10M

Paramount Gold Nevada Corp

137.45M

Can Fite Biopharma Ltd

6.59M

Whales Holding CANF

Trading Trends

People Also Watch

Frequently Asked Questions

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 3.1 USD — it has increased 2.99

What is Can Fite Biopharma Ltd (CANF)'s business?

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

What is the price predicton of CANF Stock?

Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

Can Fite Biopharma Ltd. EPS for the last quarter amounts to -3.33 USD, decreased -70.00

How many employees does Can Fite Biopharma Ltd (CANF). have?

Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of April 01 2026.

What is Can Fite Biopharma Ltd (CANF) market cap?

Today CANF has the market capitalization of 6.64M USD.